IFNA1 and systemic lupus erythematosus: Other studies stratified patients according to disease progression before and after the onset of type 1 diabetes [42], predicted the responsiveness of systemic lupus erythematosus and rheumatoid arthritis to anti-IFN therapy [43], and identified alterations in WBC gene expression profiles in those with inflammatory bowel disease [8].